Wednesday
18.45 - 20.15
Graz

The mineralocorticoid receptor: a novel target in chronic kidney disease and type 2 diabetes

Evening Session

Peter Rossing
Welcome and introduction
Paola Fioretto
CKD in T2D: how serious is this problem?
Katherine Tuttle
Inflammation and fibrosis: how does it affect CKD progression and is it a suitable treatment target?
Peter Rossing
Targeting the mineralocorticoid receptor to reduce CKD in T2D: is it time for a new treatment paradigm?
All
Q&A
Peter Rossing
Close
Symposium by:
BAYER